Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Meta Acquires AI Startup Manus to Expand Advanced AI Capabilities Across Platforms 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Bain Capital Moves to Acquire Majority Stake in Echo Marketing 
Starlink Plans Satellite Orbit Reconfiguration in 2026 to Boost Space Safety 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
March 9, 2017
AkzoNobel rejects an unsolicited indicative proposal from PPG
Akzo Nobel N.V. (AKZA.AS; AKZOY)
AkzoNobel, one of the world's leading paints, coatings and chemicals companies announces today a review of strategic options for the separation of its Specialty Chemicals business.
For the entire release, please see the enclosed pdf
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/e0a8f989-d2ea-4100-95f6-00a2f5493a70
